Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$1.46M$1.46M−69.7% vs Q1 2016 Net Income-$16.65M-$16.65MN/M vs Q1 2016 EPS Diluted-$0.65-$0.65N/M vs Q1 2016 Operating Income-$17,522,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
Free Cash Flowderived-$17,239,000N/M Margins · derivedOperating margin-1196.9%−1042.3 pt vs Q1 2016
Net margin-1137.2%−988.3 pt vs Q1 2016
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end